Northwestern University Feinberg School of Medicine, Chicago, Illinois, and Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital, Boston, Massachusetts.
Arthritis Rheumatol. 2020 Jul;72(7):1082-1090. doi: 10.1002/art.41240.
To identify the extent to which opioid prescribing rates for patients with rheumatoid arthritis (RA) vary in the US and to determine the implications of baseline opioid prescribing rates on the probability of future long-term opioid use.
We identified patients with RA from physicians who contributed ≥10 patients within the first 12 months of participation in the Corrona RA Registry. The baseline opioid prescribing rate was calculated by dividing the number of patients with RA reporting opioid use during the first 12 months by the number of patients with RA providing data that year. To estimate odds ratios (ORs) for long-term opioid use, we used generalized linear mixed models.
During the follow-up period, long-term opioid use was reported by 7.0% (163 of 2,322) of patients of physicians with a very low rate of opioid prescribing (referent) compared to 6.8% (153 of 2,254) of patients of physicians with a low prescribing rate, 12.5% (294 of 2,352) of patients of physicians with a moderate prescribing rate, and 12.7% (307 of 2,409) of patients of physicians with a high prescribing rate. The OR for long-term opioid use after the baseline period was 1.16 (95% confidence interval [95% CI] 0.79-1.70) for patients of low-intensity prescribing physicians, 1.89 (95% CI 1.27-2.82) for patients of moderate-intensity prescribing physicians, and 2.01 (95% CI 1.43-2.83) for patients of high-intensity prescribing physicians, compared to very low-intensity prescribing physicians.
Rates of opioid prescriptions vary widely. Our findings indicate that baseline opioid prescribing rates are a strong predictor of whether a patient will become a long-term opioid user in the future, after controlling for patient characteristics.
确定美国类风湿关节炎(RA)患者阿片类药物处方率的差异,并确定基线阿片类药物处方率对未来长期使用阿片类药物的可能性的影响。
我们从在 Corrona RA 登记处参与的前 12 个月内至少有 10 名患者的医生中确定了 RA 患者。通过将报告第一年中使用阿片类药物的 RA 患者人数除以当年提供数据的 RA 患者人数,计算基线阿片类药物处方率。为了估计长期使用阿片类药物的比值比(OR),我们使用了广义线性混合模型。
在随访期间,7.0%(163/2322)的医生的阿片类药物处方率非常低(参照)的患者报告长期使用阿片类药物,而医生的阿片类药物处方率较低的患者为 6.8%(153/2254),处方率中等的患者为 12.5%(294/2352),处方率高的患者为 12.7%(307/2409)。与低强度处方医生的患者相比,基线后长期使用阿片类药物的 OR 为 1.16(95%置信区间 [95%CI] 0.79-1.70),中度处方医生的患者为 1.89(95%CI 1.27-2.82),而高度处方医生的患者为 2.01(95%CI 1.43-2.83)。
阿片类药物处方率差异很大。我们的研究结果表明,在控制患者特征后,基线阿片类药物处方率是预测患者未来是否成为长期阿片类药物使用者的一个强有力指标。